Key facts
- It has raised $1.9M.
- Notable investors include CSIRO ON Accelerate, Brandon Biocatalyst, The University of Western Australia.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Cytophenix
- ·The full record, as it builds
Funding rounds
No funding rounds for Cytophenix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cytophenix
Operator of a medical diagnostic platform intended to provide rapid antimicrobial susceptibility testing. The company's platform analyzes individual bacterial and fungal cells using patented technology and proprietary artificial intelligence to deliver quantitative and comprehensive susceptibility results within hours, enabling clinicians to make timely and informed antibiotic treatment decisions for patients with serious infections.
- Sector
- Healthcare
- HQ
- Perth, Australia
- Founded
- 2023
- Employees
- 8
- Website
- cytophenix.com/
- Ownership
- Privately Held (backing)
Cytophenix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cytophenix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cytophenix in its N-PORT filings yet. We sweep new filings monthly.